NDT Advance Access originally published online on May 17, 2007
Nephrology Dialysis Transplantation 2007 22(8):2362-2365; doi:10.1093/ndt/gfm270
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism
Department of Nephrology and Hypertension, University of Berne, 3010 Berne, Switzerland
Correspondence and offprint requests to: Markus G. Mohaupt, Department of Nephrology and Hypertension, University Hospital Bern, Inselspital, Freiburgstrasse 10, CH-3010 Berne, Switzerland. Email: markus.mohaupt{at}insel.ch
 |
Abstract |
|---|
Background. Persistent hyperparathyroidism after renal transplantation affects bone and allografts. Cinacalcet, a calcimimetic, reduces serum calcium and PTH in renal transplant recipients with persistent hyperparathyroidism. Here, we address the question whether this effect of cinacalcet persists after withdrawal.
Methods. Therefore, cinacalcet was stopped after 12 months treatment in 10 stable renal transplant patients. Serum calcium, phosphate, PTH, creatinine and cystatin C were monitored for 3 months.
Results. Serum calcium, normalized in nine patients before cessation of cinacalcet (2.32 ± 0.05mmol/l, mean ± SEM), increased after 3 months of discontinuation by 0.17 ± 0.04mmol/l, P < 0.05, but remained within the normal range in eight patients. Compared with the time point of cessation, PTH remained unchanged or decreased further after 3 months without therapy in six patients. Measurements of cystatin C suggested an improvement of the glomerular filtration rate after cessation in 9 out of 10 patients (1.55 ± 0.09 vs 1.33 ± 0.12 mg/l, P < 0.01).
Conclusion. First, a beneficial effect of cinacalcet beyond the duration of a 12-month therapy appears to be present in some patients and second, the previously suspected influence of cinacalcet therapy on renal function is reversible. Thus, it is reasonable to consider a trial of cinacalcet cessation to identify these patients. The optimal time point for such a discontinuation is unknown. The present observations are preliminary. They clearly require a prospective randomized trial for definitive confirmation.
Keywords: calcimimetic; cinacalcet; hypercalcaemia; kidney transplantation; parathormone; persistent hyperparathyroidism
Received for publication: 19.10.06
Accepted in revised form: 6. 4.07
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Evenepoel, B. Van Den Bergh, M. Naesens, H. De Jonge, B. Bammens, K. Claes, D. Kuypers, and Y. Vanrenterghem Calcium Metabolism in the Early Posttransplantation Period Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 665 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Goto, H. Komaba, and M. Fukagawa Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention NDT Plus, August 1, 2008; 1(suppl_3): iii2 - iii8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tanaka, S. Nakanishi, H. Komaba, K. Itoh, K. Matsushita, and M. Fukagawa Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism NDT Plus, August 1, 2008; 1(suppl_3): iii49 - iii53. [Abstract] [Full Text] [PDF]
|
|